中文版正在生成中，先为你展示英文版分析。
AI核心结论
Stryker delivered strong FY2025 results with revenue growing 11.2% to $25.1B and operating income surging 32.5% to $4.9B, driven by robust demand across its medical device portfolio, though net income growth of 8.5% was tempered by higher SG&A and interest costs.
营业收入
$25.12B
同比 ++11.16%
每股收益（基本）
$8.49
同比 ++8.02%
毛利率
64.0%
同比 ++0.06%
营业利润
$4.89B
同比 ++32.53%
提交于 · 解读更新于 · 来源: SEC EDGAR 10-K 原文
Stryker (SYK) FY2025 营收 $25.12B，同比增长 11.2%。 净利润 $3.25B，同比增长 8.5%，稀释每股收益 $8.40。 毛利率 64.0%。
Stryker grew total revenue by 11.2% year-over-year to $25.1B in FY2025, up from $22.6B in the prior year, reflecting sustained demand for its orthopedic implants, surgical equipment, and neurotechnology products.
来源: Source: 10-K Income Statement (XBRL Financial Data)
Operating income jumped 32.5% to $4.9B, with operating margin expanding approximately 314 basis points to 19.5% from 16.3%, suggesting improved cost efficiency and favorable product mix despite rising SG&A expenses.
来源: Source: 10-K Income Statement & Key Ratios (XBRL Financial Data)
SG&A expenses rose 12.6% to $8.65B, slightly outpacing revenue growth of 11.2%, indicating continued investment in the commercial salesforce and potential integration costs related to acquisitions, which partially offset operating leverage gains.
来源: Source: 10-K Income Statement (XBRL Financial Data)
Operating cash flow increased 18.9% to $5.0B in FY2025, well above net income of $3.2B, reflecting strong earnings quality and non-cash add-backs including $1.57B in depreciation and amortization.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
Investing cash outflows surged 62.2% to -$4.87B, strongly suggesting meaningful acquisition activity in FY2025, while long-term debt rose 21.9% to $14.9B to help fund these investments.
来源: Source: 10-K Cash Flow & Balance Sheet (XBRL Financial Data)
Long-term debt increased 21.9% to $14.9B in FY2025, likely driven by acquisition financing. Elevated leverage increases interest expense, constrains financial flexibility, and could pressure net income if interest rates remain high or revenue growth slows.
来源: Source: 10-K Balance Sheet (XBRL Financial Data)
SG&A expenses grew 12.6% to $8.65B, outpacing revenue growth of 11.2%, and represent a substantial 34.4% of revenue. Sustained cost inflation in the commercial organization could erode profitability if top-line growth moderates.
来源: Source: 10-K Income Statement (XBRL Financial Data)
While operating income grew 32.5%, net income grew only 8.5% to $3.2B, implying significant below-the-line costs such as interest expense and taxes are absorbing operating gains. This gap may widen if debt levels continue to rise.
来源: Source: 10-K Income Statement (XBRL Financial Data)
Investing cash outflows of -$4.87B, up 62.2% year-over-year, indicate substantial acquisition spending. Large acquisitions carry integration execution risk, potential goodwill impairment, and cultural challenges that could disrupt operations and financial performance.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
Current assets declined slightly by 0.6% to $14.8B while current liabilities rose 2.3% to $7.8B, resulting in a current ratio of approximately 1.89. While still healthy, continued pressure on working capital could tighten near-term liquidity if operating conditions deteriorate.
来源: Source: 10-K Balance Sheet & Key Ratios (XBRL Financial Data)
FY2025 实际 EPS $4.47，分析师一致预期 $4.44，超预期 +0.7%。
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营业收入 | $25.12B | $22.59B | +11.16% |
营业成本 | $9.05B | $8.15B | +10.99% |
毛利润 | $16.07B | $14.44B | +11.25% |
营业利润 | $4.89B | $3.69B | +32.53% |
净利润 | $3.25B | $2.99B | +8.45% |
每股收益（基本） | $8.49 | $7.86 | +8.02% |
每股收益（稀释） | $8.40 | $7.76 | +8.25% |
研发费用 | $1.62B | $1.47B | +10.71% |
销售及管理费用 | $8.65B | $7.68B | +12.57% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
总资产 | $47.84B | $42.97B | +11.34% |
流动资产 | $14.76B | $14.85B | -0.62% |
总负债 | $25.42B | $22.34B | +13.82% |
流动负债 | $7.79B | $7.62B | +2.34% |
现金及等价物 | $4.01B | $3.65B | +9.83% |
长期债务 | $14.86B | $12.19B | +21.91% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
经营活动现金流 | $5.04B | $4.24B | +18.91% |
投资活动现金流 | $-4.87B | $-3B | -62.20% |
筹资活动现金流 | $113M | $-525M | +121.52% |
股息支出 | $1.28B | $1.22B | +5.33% |
折旧及摊销 | $1.57B | $1.43B | +10.10% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
毛利率 | 64.0% | 63.9% | +0.06% |
营业利润率 | 19.5% | 16.3% | +3.14% |
净利率 | 12.9% | — | — |
总资产收益率 | 6.8% | — | — |
流动比率 | $1.893 | — | — |
Health Care Equipment 行业其他公司
Stryker's revenue grew 11.2% year-over-year to $25.1B in FY2025, up from $22.6B in the prior year. This growth reflects strong demand across its medical device portfolio including orthopedics, surgical equipment, and neurotechnology products.
The standout result in Stryker's FY2025 10-K was the 32.5% surge in operating income to $4.9B, with operating margin expanding over 300 basis points to 19.5%. However, net income grew a more modest 8.5% to $3.2B, suggesting rising interest costs from a 21.9% increase in long-term debt to $14.9B are absorbing some of the operating gains.
Yes, Stryker generated $5.0B in operating cash flow in FY2025, an 18.9% increase over the prior year's $4.2B, and well above net income of $3.2B, indicating high earnings quality. The company also paid $1.28B in dividends, reflecting its commitment to returning capital to shareholders.
Based on the financial data, key risks include Stryker's rising long-term debt (up 21.9% to $14.9B), likely driven by significant acquisition activity (investing outflows of -$4.87B), and SG&A expense growth of 12.6% outpacing revenue growth of 11.2%. Integration risk from M&A activity and the potential for higher interest expense to further compress net margins are the most notable concerns.
Stryker paid $1.28B in dividends in FY2025, a 5.3% increase from $1.22B in the prior year, demonstrating continued commitment to dividend growth. This payout is well-covered by operating cash flow of $5.0B, suggesting the dividend is sustainable.